Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
Aptevo Therapeutics (NASDAQ:APVO) has initiated the Phase 1b/2 'RAINIER' trial for its lead candidate mipletamig (formerly APVO436) in combination with venetoclax and azacitidine for frontline acute myeloid leukemia (AML) patients. The study aims to identify the recommended Phase 2 dose and evaluate safety, tolerability, and efficacy. Previous trials showed promising results, including a 75% complete response rate among frontline patients and efficacy outcomes more than double the benchmarks. The multi-center, open-label dose-finding study will enroll up to 39 patients across five dose levels. Primary endpoints include safety assessment, determining the maximum tolerated dose, and evaluating cytokine release syndrome incidence.
Aptevo Therapeutics (NASDAQ:APVO) ha avviato il trial di Fase 1b/2 'RAINIER' per il suo principale candidato mipletamig (precedentemente APVO436) in combinazione con venetoclax e azacitidina per pazienti con leucemia mieloide acuta (LMA) in prima linea. Lo studio mira a identificare la dose raccomandata per la Fase 2 e a valutare sicurezza, tollerabilità ed efficacia. I trial precedenti hanno mostrato risultati promettenti, tra cui un tasso di risposta completa del 75% tra i pazienti in prima linea e risultati di efficacia superiori al doppio dei benchmark. Lo studio multicentrico, open-label per la ricerca di dosaggio, prevede di arruolare fino a 39 pazienti in cinque livelli di dose. Gli endpoint primari includono la valutazione della sicurezza, la determinazione della dose massima tollerata e la valutazione dell'incidenza della sindrome da rilascio di citochine.
Aptevo Therapeutics (NASDAQ:APVO) ha iniciado el ensayo de Fase 1b/2 'RAINIER' para su candidato principal mipletamig (anteriormente APVO436) en combinación con venetoclax y azacitidina para pacientes con leucemia mieloide aguda (LMA) en primera línea. El estudio tiene como objetivo identificar la dosis recomendada para la Fase 2 y evaluar la seguridad, tolerabilidad y eficacia. Ensayos previos mostraron resultados prometedores, incluyendo un 75% de tasa de respuesta completa entre los pacientes de primera línea y resultados de eficacia que superaron más del doble los parámetros de referencia. El estudio multicéntrico, abierto y de búsqueda de dosis inscribirá hasta 39 pacientes en cinco niveles de dosis. Los puntos finales primarios incluyen la evaluación de la seguridad, la determinación de la dosis máxima tolerada y la evaluación de la incidencia del síndrome de liberación de citoquinas.
Aptevo Therapeutics (NASDAQ:APVO)는 급성 골수성 백혈병 (AML) 환자를 위한 1b/2상 'RAINIER' 시험을 시작했습니다. 이 시험은 주요 후보인 mipletamig (이전 명칭 APVO436)과 venetoclax 및 azacitidine 조합을 평가합니다. 연구의 목적은 2상 권장 용량을 확인하고 안전성, 내약성 및 효능을 평가하는 것입니다. 이전 시험에서는 주요 환자들 사이에서 75%의 완전 반응률과 기준치를 두 배 이상 초과하는 효능 결과가 포함된 유망한 결과가 나타났습니다. 이 다기관, 공개형 용량 탐색 연구에서는 5개의 용량 수준에 걸쳐 최대 39명의 환자가 등록됩니다. 주요 목표는 안전성 평가, 최대 내약 용량 결정, 그리고 사이토카인 방출 증후군 발생률 평가를 포함합니다.
Aptevo Therapeutics (NASDAQ:APVO) a lancé l'essai de Phase 1b/2 'RAINIER' pour son candidat principal mipletamig (anciennement APVO436) en combinaison avec venetoclax et azacitidine pour les patients présentant une leucémie myéloïde aiguë (LMA) en première ligne. L'étude vise à identifier la dose recommandée pour la Phase 2 et à évaluer la sécurité, la tolérance et l'efficacité. Les essais précédents ont montré des résultats prometteurs, y compris un taux de réponse complète de 75% parmi les patients en première ligne et des résultats d'efficacité plus de deux fois supérieurs aux références. L'étude multicentrique, à ouvert et d'exploration de dose, prévoit d'inscrire jusqu'à 39 patients dans cinq niveaux de dose. Les critères d'évaluation principaux comprennent l'évaluation de la sécurité, la détermination de la dose maximale tolérée et l'évaluation de l'incidence du syndrome de libération de cytokines.
Aptevo Therapeutics (NASDAQ:APVO) hat die Phase 1b/2-Studie 'RAINIER' für seinen Hauptkandidaten mipletamig (ehemals APVO436) in Kombination mit Venetoclax und Azacitidin für Patienten mit akuter myeloischer Leukämie (AML) in der Erstbehandlung gestartet. Die Studie zielt darauf ab, die empfohlene Dosis für die Phase 2 zu identifizieren und Sicherheit, Verträglichkeit und Wirksamkeit zu bewerten. Frühere Studien zeigten vielversprechende Ergebnisse, darunter eine 75%ige vollständige Ansprechrate bei Erstbehandlungs-Patienten und Wirksamkeitsresultate, die die Benchmarks mehr als verdoppeln. Die multizentrische, offene Dosierungserhebung wird bis zu 39 Patienten in fünf Dosisstufen einschreiben. Zu den primären Endpunkten gehören die Bewertung der Sicherheit, die Bestimmung der maximal tolerierten Dosis und die Untersuchung der Inzidenz des Zytokinfreisetzungssyndroms.
- Initiation of Phase 1b/2 'RAINIER' trial for mipletamig in frontline AML
- Previous trials showed 75% complete response rate in frontline patients
- Efficacy outcomes more than double the reported benchmarks
- 91% clinical benefit rate in combination therapy for venetoclax naïve patients
- Clinically meaningful duration of remission with no median reached
- 27% of patients experienced cytokine release syndrome in previous trials
Insights
The initiation of the Phase 1b/2 RAINIER trial for mipletamig (APVO436) in frontline AML is a significant development. This study aims to optimize dosing and further evaluate the drug's efficacy in combination with standard-of-care venetoclax and azacitidine. Key points:
- The trial will enroll up to 39 patients across five dose levels (9-140 mcg)
- Primary endpoints focus on safety, tolerability and determining the recommended Phase 2 dose
- Previous data showed promising results:
75% complete response rate in frontline patients and91% clinical benefit rate in combination therapy - Low incidence of cytokine release syndrome (
27% ) compared to competitors
If successful, this trial could position mipletamig as a potential game-changer in AML treatment, particularly for patients ineligible for intensive chemotherapy.
The RAINIER trial for mipletamig in frontline AML is an exciting development in leukemia treatment. The combination of mipletamig with venetoclax and azacitidine could potentially address unmet needs in AML therapy. Notable aspects include:
- Focus on patients ineligible for intensive induction chemotherapy, a challenging-to-treat population
- Previous
75% complete response rate in frontline patients is remarkably high for AML - The
91% clinical benefit rate in venetoclax-naive patients exceeds benchmarks, suggesting potential superiority over current standards - Lower incidence of cytokine release syndrome (
27% ) could translate to better tolerability and safety profile
If these results are replicated in the RAINIER trial, it could lead to a paradigm shift in frontline AML treatment, potentially improving outcomes for this difficult-to-treat malignancy.
The initiation of the RAINIER trial for mipletamig (APVO436) is a positive development for Aptevo Therapeutics (NASDAQ:APVO). Key financial implications:
- Potential market expansion: Targeting frontline AML patients ineligible for intensive chemotherapy addresses a significant unmet need
- Competitive advantage: Previous data showing efficacy outcomes more than double the benchmarks could lead to market leadership if confirmed
- Risk mitigation: Prior safety data and low incidence of cytokine release syndrome may reduce clinical trial risks
- Partnership potential: Strong results could attract big pharma interest for licensing or acquisition
- Long-term value: Success could position Aptevo as a key player in the lucrative oncology market
However, investors should note that clinical trial outcomes remain uncertain and the company may require additional funding to complete development. Overall, this news represents a significant milestone in Aptevo's pipeline progression.
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidine
Company anticipates new data set to bolster existing compelling data reported to date, including efficacy outcomes more than double the benchmarks*
Outcomes also expected to identify recommended Phase 2 dose
APVO436 renamed as mipletamig: Aptevo adopts new generic name for future use
SEATTLE, WA / ACCESSWIRE / August 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today, announced initiation of the Company's Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate APVO436 in combination with venetoclax + azacitidine for frontline patients with acute myeloid leukemia (AML). RAINIER will be conducted in two parts. First, a Phase 1b frontline AML study followed by a Phase 2 study. The Company also announced that APVO436 has received its generic name, mipletamig (mih-ple'-tah-mig) and will refer to its lead candidate by this name moving forward.
"With a strong foundation of positive clinical data demonstrating safety, tolerability, efficacy, and durability, we are thrilled to announce the initiation of our Phase 1b/2 RAINIER study. This trial aims to identify the recommended Phase 2 dose and further evaluate key indicators-such as safety, tolerability, and efficacy-of mipletamig when combined with standard of care venetoclax and azacitidine in frontline AML patients," stated Marvin White, President and CEO of Aptevo. "Mipletamig has already been administered to 90 patients across two trials, both as a monotherapy and in combination therapy, with results showing an exceptional safety profile and efficacy outcomes more than double those reported in the literature and a
This frontline AML study is a multi-center, multi-cohort, open label dose finding study of up to 39 patients across five dose levels ranging from 9 mcg - 140 mcg in combination with venetoclax and azacitidine (ven/aza). Subjects will be adults aged 18 or older, newly diagnosed with AML who are not eligible for intensive induction chemotherapy. Phase 1b consists of 28-day cycles of treatment in five sequential cohorts. Aptevo has partnered with Prometrika (https://www.prometrika.com/), a premier contract research organization, for the RAINIER trial.
Primary endpoints:
Evaluate the safety, tolerability, and maximum tolerated dose (MTD) of increasing doses of APVO436 in combination with venetoclax and azacitidine in patients with newly diagnosed AML
Determine the recommended Phase 2 dose
Assess incidence of cytokine release syndrome (CRS) at each dose level
*Benchmark Composite References: Aldoss 2019, Maiti 2021, Morsia 2020, Garciaz 2022, Feld 2021
Secondary Endpoint:
Determine the efficacy of increasing doses of APVO436 in combination with venetoclax and azacitidine in patients with newly diagnosed AML
"The initiation of our RAINIER trial marks a critical milestone in the clinical development of our lead candidate, mipletamig, in combination therapy for frontline AML," said Dirk Huebner, MD, Chief Medical Officer at Aptevo. "In this dose optimization trial, we will administer a combination of venetoclax, azacitidine, and mipletamig across up to five different dose levels. Our primary objective is to identify the optimal Phase 2 dose while continuing to assess the safety, tolerability, efficacy, and durability of remission. By focusing on frontline patients with this combination therapy, we aim to gain deeper insights into the role of mipletamig within the triplet regimen and its potential to improve treatment outcomes."
Prior Outcomes: Compelling Results to Date
Dose Escalation (monotherapy)
2 complete remissions (CRs) reported in AML patients who received the drug as a monotherapy
Most CRS cases were low-grade and clinically manageable
Dose Expansion (combination therapy)
91% clinical benefit rate in combination with standard of care venetoclax + azacitidine in venetoclax naïve patients which exceeds our benchmark (Benchmark Composite References: Aldoss 2019, Maiti 2021, Morsia 2020, Garciaz 2022, Feld 2021)75% of frontline patients experienced a CR
Clinically meaningful duration of remission, with no median reached - multiple patients either stayed on treatment or moved to transplant
Only
27% of patients experienced CRS (cytokine release syndrome), which is favorable compared to competitor drugs.Most CRS cases were low-grade and clinically manageable
About Mipletamig
Aptevo's wholly owned lead proprietary drug candidate, mipletamig, targeting AML, MDS and other leukemias, is differentiated by design to redirect the immune system of the patient to destroy leukemic cells and leukemic stem cells expressing the target antigen CD123, which is a compelling target for AML due to its overexpression on leukemic stem cells and AML blasts. This antibody-like recombinant protein therapeutic is designed to engage both leukemic cells and T cells of the immune system and bring them closely together to trigger the destruction of leukemic cells. Mipletamig is purposefully designed to reduce the likelihood and severity of CRS by use of a unique CD3 derived from CRIS-7 vs. the CD3 used by other competitors. Mipletamig has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act. Mipletamig has been evaluated in 90 patients over two trials to date. RAINIER, Aptevo's Phase 1b/2 frontline AML program, was initiated in 3Q24.
About Aptevo Therapeutics
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. Aptevo is seeking to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements regarding advancement of Aptevo's therapeutic candidates in clinical trials, including the initiation of the Phase 1b/2 dose optimization trial to further evaluate mipletamig in combination with venetoclax and azacitidine , whether the Phase 1b/2 protocol will be successful, whether further study of mipletamig in Phase 1b/2 trial focusing on a targeted patient population will continue to show clinical benefit, whether Aptevo's strategy will translate into an improved overall survival rate in acute myeloid leukemia, statements related to the durability of mipletamig and whether its duration of remission results will be indicative of later stage clinical trials, whether the mipletamig data in combination therapy and monotherapy will be indicative of later stage clinical trials, mipletamig's potential for multiple indications, the timing for its expected data readouts and whether this trial will establish a recommended Phase 2 dose, the potential use of any such candidate as therapeutics for treatment of disease, expectations about the safety, tolerability, efficacy and durability of its therapeutic candidate, statements regarding preclinical and clinical results and any suggestion that those results will be replicated in clinical development, the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, and any other statements containing the words "may," "believes," "expects," "potential," "designed," "engineered," "innovative," "initiate," "allow," "promise," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social, macroeconomic, and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation, enrollment and maintenance of patients in clinical trials, uncertainties inherent in the results of preliminary or interim data and preclinical and clinical studies being predictive of the results of later-stage clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of the Company's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine as well as the war between Israel and Hamas, and macroeconomic conditions such as rising inflation and interests rates, increased market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
Aptevo Therapeutics
Miriam Weber Miller
Email: IR@apvo.com or millerm@apvo.com
Phone: 206-859-6629
SOURCE: Aptevo Therapeutics
View the original press release on accesswire.com
FAQ
What is the purpose of Aptevo's RAINIER trial for mipletamig (APVO436)?
What were the key results from previous trials of mipletamig (APVO436)?
How many patients will be enrolled in the RAINIER trial for APVO?